ACRV - CIK 0001781174
Acrivon Therapeutics, Inc. (ACRV) reported net income of -$77.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$77.91M | +3.3% |
| FY 2024 | -$80.56M | -33.4% |
| FY 2023 | -$60.39M | -93.8% |
| FY 2022 | -$31.17M | -91.9% |
| FY 2021 | -$16.24M | - |
Acrivon Therapeutics, Inc. (ACRV) reported net income of -$77.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, Acrivon Therapeutics, Inc.'s net income declined from -$16.24M to -$77.91M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.